A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University identified an antibody that attacks SARS-CoV-2, the virus that causes COVID-19, but also its variants and other types of coronaviruses.

AstraZeneca is creating a separate division for vaccines and antibody therapies, the drugmaker said on November 9, to focus on the company’s Covid-19 shot and the development of coronavirus treatments after a series of setbacks during the pandemic.

U.S. health officials and politicians pleaded with Americans to stay at home over the Thanksgiving holiday and abide by constraints placed on social and economic life as record coronavirus caseloads pushed hospitals to their limits.

Zymeworks and longtime partner Merck signed a new license agreement. Merck was granted the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.